JP2007509891A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007509891A5 JP2007509891A5 JP2006537197A JP2006537197A JP2007509891A5 JP 2007509891 A5 JP2007509891 A5 JP 2007509891A5 JP 2006537197 A JP2006537197 A JP 2006537197A JP 2006537197 A JP2006537197 A JP 2006537197A JP 2007509891 A5 JP2007509891 A5 JP 2007509891A5
- Authority
- JP
- Japan
- Prior art keywords
- active ingredient
- formulation according
- formulation
- salt
- film
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 28
- 238000009472 formulation Methods 0.000 claims description 23
- 239000004480 active ingredient Substances 0.000 claims description 15
- -1 fatty acid salt Chemical class 0.000 claims description 13
- 229920000642 polymer Polymers 0.000 claims description 12
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 10
- 239000000194 fatty acid Substances 0.000 claims description 10
- 229930195729 fatty acid Natural products 0.000 claims description 10
- 239000002356 single layer Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims 7
- 238000002360 preparation method Methods 0.000 claims 5
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 4
- 239000002518 antifoaming agent Substances 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 150000004665 fatty acids Chemical class 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 229910052783 alkali metal Inorganic materials 0.000 claims 3
- 239000008188 pellet Substances 0.000 claims 3
- 239000003381 stabilizer Substances 0.000 claims 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- 229910052749 magnesium Inorganic materials 0.000 claims 2
- 239000011777 magnesium Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008185 minitablet Substances 0.000 claims 2
- 239000002736 nonionic surfactant Substances 0.000 claims 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 2
- 229920000058 polyacrylate Polymers 0.000 claims 2
- 229910052700 potassium Inorganic materials 0.000 claims 2
- 239000011591 potassium Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 claims 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 239000005639 Lauric acid Substances 0.000 claims 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 1
- RGHAZVBIOOEVQX-UHFFFAOYSA-N Metoprolol succinate Chemical compound OC(=O)CCC(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 RGHAZVBIOOEVQX-UHFFFAOYSA-N 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 239000004113 Sepiolite Substances 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 claims 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims 1
- 239000004147 Sorbitan trioleate Substances 0.000 claims 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 claims 1
- NCHJGQKLPRTMAO-XWVZOOPGSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NCHJGQKLPRTMAO-XWVZOOPGSA-N 0.000 claims 1
- 125000005396 acrylic acid ester group Chemical group 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 239000003945 anionic surfactant Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 229960000892 attapulgite Drugs 0.000 claims 1
- 239000000440 bentonite Substances 0.000 claims 1
- 229910000278 bentonite Inorganic materials 0.000 claims 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims 1
- 229960000686 benzalkonium chloride Drugs 0.000 claims 1
- 229960001950 benzethonium chloride Drugs 0.000 claims 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 1
- 239000003093 cationic surfactant Substances 0.000 claims 1
- 229960002798 cetrimide Drugs 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 claims 1
- YGANSGVIUGARFR-UHFFFAOYSA-N dipotassium dioxosilane oxo(oxoalumanyloxy)alumane oxygen(2-) Chemical compound [O--].[K+].[K+].O=[Si]=O.O=[Al]O[Al]=O YGANSGVIUGARFR-UHFFFAOYSA-N 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 229940075507 glyceryl monostearate Drugs 0.000 claims 1
- 239000002563 ionic surfactant Substances 0.000 claims 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims 1
- 229910052622 kaolinite Inorganic materials 0.000 claims 1
- 159000000003 magnesium salts Chemical class 0.000 claims 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960002237 metoprolol Drugs 0.000 claims 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims 1
- 229960000939 metoprolol succinate Drugs 0.000 claims 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 claims 1
- 229910052901 montmorillonite Inorganic materials 0.000 claims 1
- 229910052627 muscovite Inorganic materials 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- 229960002446 octanoic acid Drugs 0.000 claims 1
- 229910052625 palygorskite Inorganic materials 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 229940068965 polysorbates Drugs 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 229910052903 pyrophyllite Inorganic materials 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229910052624 sepiolite Inorganic materials 0.000 claims 1
- 235000019355 sepiolite Nutrition 0.000 claims 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims 1
- CVYDEWKUJFCYJO-UHFFFAOYSA-M sodium;docosanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCCCCC([O-])=O CVYDEWKUJFCYJO-UHFFFAOYSA-M 0.000 claims 1
- 229940035044 sorbitan monolaurate Drugs 0.000 claims 1
- 239000001593 sorbitan monooleate Substances 0.000 claims 1
- 235000011069 sorbitan monooleate Nutrition 0.000 claims 1
- 229940035049 sorbitan monooleate Drugs 0.000 claims 1
- 239000001570 sorbitan monopalmitate Substances 0.000 claims 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 claims 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 claims 1
- 239000001587 sorbitan monostearate Substances 0.000 claims 1
- 235000011076 sorbitan monostearate Nutrition 0.000 claims 1
- 229940035048 sorbitan monostearate Drugs 0.000 claims 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 claims 1
- 235000019337 sorbitan trioleate Nutrition 0.000 claims 1
- 229960000391 sorbitan trioleate Drugs 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 235000012222 talc Nutrition 0.000 claims 1
- 229910052902 vermiculite Inorganic materials 0.000 claims 1
- 239000010455 vermiculite Substances 0.000 claims 1
- 235000019354 vermiculite Nutrition 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2003151301 DE10351301A1 (de) | 2003-10-31 | 2003-10-31 | Retardierte Dosisform aus mehreren Einzeleinheiten |
| DE200410014828 DE102004014828A1 (de) | 2004-03-24 | 2004-03-24 | Pharmazeutische wirkstoffhaltige Formulierung mit Überzug |
| PCT/EP2004/012230 WO2005041934A2 (de) | 2003-10-31 | 2004-10-28 | Pharmazeutische wirkstoffhaltige formulierung mit überzug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007509891A JP2007509891A (ja) | 2007-04-19 |
| JP2007509891A5 true JP2007509891A5 (OSRAM) | 2007-12-13 |
Family
ID=34553325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006537197A Pending JP2007509891A (ja) | 2003-10-31 | 2004-10-28 | コーティングを有する薬学的活性成分含有製剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080254112A1 (OSRAM) |
| EP (1) | EP1677766B1 (OSRAM) |
| JP (1) | JP2007509891A (OSRAM) |
| AT (1) | ATE549015T1 (OSRAM) |
| AU (1) | AU2004285284B2 (OSRAM) |
| BR (1) | BRPI0415557A (OSRAM) |
| CA (1) | CA2543689A1 (OSRAM) |
| MX (1) | MXPA06004700A (OSRAM) |
| NO (1) | NO20062051L (OSRAM) |
| NZ (1) | NZ547284A (OSRAM) |
| RU (1) | RU2372893C2 (OSRAM) |
| WO (1) | WO2005041934A2 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005024614A1 (de) * | 2005-05-25 | 2006-11-30 | Röhm Gmbh | Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug |
| WO2007097770A1 (en) * | 2006-02-24 | 2007-08-30 | Teva Pharmaceutical Industries Ltd. | Metoprolol succinate e.r. tablets and methods for their preparation |
| CA2953372C (en) * | 2006-09-26 | 2020-06-23 | Novartis Ag | Pharmaceutical composition comprising an s1p receptor modulator |
| EP2184056B1 (en) | 2007-08-27 | 2019-04-24 | Asahi Kasei Kabushiki Kaisha | Process for production of tablets containing both crystalline cellulose and granules |
| US9555006B2 (en) * | 2007-09-21 | 2017-01-31 | Evonik Roehm Gmbh | PH-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol |
| KR101424653B1 (ko) * | 2007-09-21 | 2014-08-06 | 에보니크 룀 게엠베하 | 에탄올의 영향에 대하여 내성을 가지는 ｐｈ-의존성 조절 방출 제약학적 오피오이드 조성물 |
| US20110070302A2 (en) * | 2008-01-10 | 2011-03-24 | Evonik Roehm Gmbh | Coated pharmaceutical or nutraceutical preparation with accelerated controlled active substance release |
| ES2715274T3 (es) | 2008-01-10 | 2019-06-03 | Evonik Roehm Gmbh | Preparación farmacéutica o nutracéutica recubierta con liberación de sustancias activas mejorada |
| EP2309999A1 (en) * | 2008-06-26 | 2011-04-20 | McNeil-PPC, Inc. | Coated particles containing pharmaceutically active agents |
| EP2329823A4 (en) | 2008-09-03 | 2013-04-03 | Takeda Pharmaceutical | PROCESS FOR INCREASING THE ABSORPTION ABILITY OF A PREPARATION AND PREPARATION WITH INCREASED ABSORPTION ABILITY |
| CA2755808C (en) * | 2009-03-18 | 2016-01-19 | Evonik Roehm Gmbh | Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients |
| JP5619131B2 (ja) * | 2009-03-18 | 2014-11-05 | エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツングＥｖｏｎｉｋ ＲｏｅｈｍＧｍｂＨ | ポリマー混合物と賦形剤とを含むコーティングを使用するエタノールの影響に対する耐性を有する制御放出性医薬組成物 |
| MX2011011919A (es) * | 2009-05-12 | 2012-01-27 | Bpsi Holdings Llc | Sistemas de recubrimiento de pelicula de liberacion inmediata con barrera contra humedad mejorada y sustratos recubiertos con dichos sistemas. |
| KR20120033305A (ko) * | 2009-05-12 | 2012-04-06 | 비피에스아이 홀딩스, 엘엘씨. | 미립자인 비점착제를 포함하는 필름 코팅 및 상기 필름코팅이 코팅된 기재 |
| BR112012027782A2 (pt) | 2010-04-30 | 2016-08-02 | Takeda Pharmaceutical | tablete entérico |
| KR101820181B1 (ko) | 2010-04-30 | 2018-02-28 | 다케다 야쿠힌 고교 가부시키가이샤 | 장용성 정제 |
| FR2968559B1 (fr) * | 2010-12-14 | 2012-12-28 | Alexandra Fregonese | Nouvelles compositions a base d'argile et de beepollen, leur procede de preparation et leurs utilisations en nutrition et en therapeutique |
| MX347961B (es) * | 2011-09-16 | 2017-05-19 | Purdue Pharma Lp | Formulaciones de liberación inmediata resistentes a alteración. |
| MX355478B (es) * | 2011-09-16 | 2018-04-19 | Purdue Pharma Lp | Formulaciones farmacéuticas resistentes a la manipulación. |
| EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| WO2021030550A1 (en) | 2019-08-13 | 2021-02-18 | Mccord Darlene E | NON-ACTIVATED, AMORPHOUS, pH NEUTRAL, TWO-PART BEDSIDE-READY CLAY DELIVERY SYSTEM THAT TREATS PATHOGEN INFECTIONS IN HUMANS AND ANIMALS |
| JP7482645B2 (ja) * | 2020-02-18 | 2024-05-14 | 沢井製薬株式会社 | 核粒子を含む顆粒の製造方法 |
| EP4423197A4 (en) | 2021-10-25 | 2025-08-27 | Darlene E Mccord | COATED MEDICINAL CLAY COMPOSITIONS, PHARMACEUTICAL COMPOSITIONS AND DELIVERY OF CATION SOURCES AND METHODS OF USE THEREOF |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5110814A (en) * | 1989-01-11 | 1992-05-05 | Asta Pharma Ag | Azelastine and its salts used to combat psoriasis |
| DE3900811A1 (de) * | 1989-01-13 | 1990-07-19 | Kali Chemie Pharma Gmbh | Neue arzneiform |
| CH687810A5 (de) * | 1995-05-24 | 1997-02-28 | Mepha Ag | Pelletformulierung mit Omeprazol. |
| CA2177769C (en) * | 1995-06-07 | 1999-08-24 | Gyanesh P. Khare | Particulate compositions that comprise zinc aluminate |
| DE19732903A1 (de) * | 1997-07-30 | 1999-02-04 | Falk Pharma Gmbh | Pellet-Formulierung zur Behandlung des Intestinaltraktes |
| CN1277550A (zh) * | 1997-09-11 | 2000-12-20 | 尼科梅德丹麦有限公司 | 非甾体抗炎药物(NSAIDs)的改进释放的复合型组合物 |
| ES2559766T3 (es) * | 1998-05-18 | 2016-02-15 | Takeda Pharmaceutical Company Limited | Comprimidos disgregables en la boca |
| DE19905906A1 (de) * | 1999-02-11 | 2000-08-17 | Basf Ag | Verwendung von wasserlöslichen oder wasserdispergierbaren Polyether-haltigen Polymerisaten als Überzugsmittel, Bindemittel und/oder filmbildender Hilfsstoff in pharmazeutischen Darreichungsformen |
| DE19850238A1 (de) * | 1998-10-31 | 2000-05-04 | Triple Trian Beteiligungs Gmbh | Verfahren und Vorrichtung zur Kompensation von Elektrosmog |
| US7070803B2 (en) * | 2000-03-31 | 2006-07-04 | Nycomed Austria Gmbh | Controlled release pharmaceutical composition for oral use containing midodrine and/or active metabolite, desglymidodrine |
| US6749867B2 (en) * | 2000-11-29 | 2004-06-15 | Joseph R. Robinson | Delivery system for omeprazole and its salts |
| SE0100200D0 (sv) * | 2001-01-24 | 2001-01-24 | Astrazeneca Ab | New film coating |
| DE10149674A1 (de) * | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
| WO2003051340A1 (en) * | 2001-12-19 | 2003-06-26 | Astrazeneca Ab | New film coating |
| AU2004263130A1 (en) * | 2003-08-06 | 2005-02-17 | Nirmal Mulye | Pharmaceutical composition containing water soluble drug |
-
2004
- 2004-10-28 NZ NZ547284A patent/NZ547284A/en not_active IP Right Cessation
- 2004-10-28 CA CA002543689A patent/CA2543689A1/en not_active Abandoned
- 2004-10-28 MX MXPA06004700A patent/MXPA06004700A/es active IP Right Grant
- 2004-10-28 BR BRPI0415557-2A patent/BRPI0415557A/pt not_active Application Discontinuation
- 2004-10-28 AU AU2004285284A patent/AU2004285284B2/en not_active Ceased
- 2004-10-28 WO PCT/EP2004/012230 patent/WO2005041934A2/de not_active Ceased
- 2004-10-28 AT AT04790997T patent/ATE549015T1/de active
- 2004-10-28 JP JP2006537197A patent/JP2007509891A/ja active Pending
- 2004-10-28 EP EP04790997A patent/EP1677766B1/de not_active Revoked
- 2004-10-28 US US10/577,569 patent/US20080254112A1/en not_active Abandoned
- 2004-10-28 RU RU2006118689/15A patent/RU2372893C2/ru not_active IP Right Cessation
-
2006
- 2006-05-08 NO NO20062051A patent/NO20062051L/no unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007509891A5 (OSRAM) | ||
| JP6561105B2 (ja) | 過活動膀胱の治療のための医薬製剤 | |
| RU2372893C2 (ru) | Содержащий фармацевтический агент состав с покрытием | |
| JP2016034947A (ja) | Ｊａｋ３インヒビターを含む制御型経口投与製剤 | |
| TW200524643A (en) | Pantoprazole multiparticulate formulations | |
| JP6759426B2 (ja) | Ｃｎｓ化合物の安定化製剤 | |
| JP2011503017A (ja) | ヒドロモルホン含有徐放性錠剤 | |
| FI3324948T3 (fi) | Monikerroksisia farmaseuttisesti aktiivista yhdistettä vapauttavia mikropartikkeleita nestemäisessä annosmuodossa | |
| TWI480067B (zh) | 經包衣之固體製劑 | |
| CN104136004A (zh) | 多西拉敏和吡哆醇和/或其代谢物或盐的制剂 | |
| JP2023505329A (ja) | リオシグアトの放出調節医薬組成物 | |
| JP5644495B2 (ja) | 被覆固形製剤 | |
| US20150366807A1 (en) | Oral pharmaceutical composition comprising dabigatran etexilate | |
| US20070196463A1 (en) | Enteric Soft Gelatin Capsule Containing Esomerpazole And Method Of Preparation | |
| WO2017103945A1 (en) | Pharmaceutical compositions | |
| WO2014060561A1 (en) | Oral pharmaceutical formulations comprising dabigatran | |
| WO2016142821A2 (en) | Compositions containing a thrombin inhibitor | |
| JP5664225B2 (ja) | 不快味マスキング粒子及びこれを含有する経口製剤 | |
| JP2015086194A (ja) | ラベプラゾールナトリウム含有粒子の製造方法及びそれを含む医薬組成物 | |
| WO2017026950A1 (en) | Controlled release propiverine formulations | |
| US20070092568A1 (en) | Galantamine compositions | |
| JPWO2015046383A1 (ja) | 原薬含有核の製造方法、原薬含有核、医薬品組成物、及び口腔内崩壊錠 | |
| US20100303920A1 (en) | Aqueous Film Coating Composition / 841 | |
| WO2009047800A2 (en) | Oral controlled release composition of carvedilol | |
| JP6086520B2 (ja) | 薬物高含有固形製剤 |